SonALAsense
Mark de Souza is a seasoned executive with extensive experience in the biotechnology and pharmaceuticals sectors. Currently serving as President and CEO at SonALAsense since January 2019, Mark has also held prominent positions such as Co-Founder and President at Willow Neuroscience and Co-Founder and Executive Chairman at Flightpath Biosciences, Inc. Mark's expertise extends to significant roles in various startups, including Co-Founder and Board Member at Phoenicis Therapeutics and NFlection Therapeutics, as well as leadership positions at Chromaderm Inc, FIBRX Derm, Inc., and SeylanMED, LLC. Additionally, Mark contributed as Executive Chairman at PellePharm and served as a consultant for Shire.
This person is not in any teams
SonALAsense
SonALAsense develops SDT (Sonodynamic Therapy) intended to turn glioblastoma multiforme (GBM) patients into cancer survivors. It utilizes MRI-guided focused ultrasound (the device) in combination with aminolevulinic acid (a drug) to selectively target and kill tumor cells. Their use of an MRI-guided focused ultrasound device with ALA is a truedrug-device combination, where both the drug and the device are required for a therapeutic effect. SDT has a well-elucidated mechanism of action (creation of reactive oxygen species). The company was founded in 2019 and is based in Berkeley, California.